SCHEMBL17816360

SCHEMBL17816360

CSc1ncnc2c1ccn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O

nearest known ligand 0.71

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
SLC29A1 Q99808 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL315725 0.85 ADK (0.62) SLC29A1
SCHEMBL18595743 0.84 ADK (0.64) SLC29A1
SCHEMBL17816352 0.84 ADK (0.64) SLC29A1
SCHEMBL18009703 0.84 ADK (0.64) SLC29A1
SCHEMBL17800853 0.84 ADK (0.64) SLC29A1
SCHEMBL537999 0.83 P2RY2 (0.61) SLC29A1
SCHEMBL10049946 0.83 P2RY2 (0.61) SLC29A1
SCHEMBL537998 0.83 P2RY2 (0.61) SLC29A1
Immunicillin H SCHEMBL31416024 0.83 ADK (0.65) SLC29A1
Tubercidin SCHEMBL23982115 0.82 ADK (0.82) SLC29A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9586986-B2 Substituted 7-deazapurine ribonucleosides for therapeutic uses INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) 2017-03-07 US disclosed
US-9586986-B2 Substituted 7-deazapurine ribonucleosides for therapeutic uses INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) 2017-03-07 US disclosed
US-20160159844-A1 NOVEL SUBSTITUTED 7-DEAZAPURINE RIBONUCLEOSIDES FOR THERAPEUTIC USES INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) 2016-06-09 US disclosed
US-20160159844-A1 NOVEL SUBSTITUTED 7-DEAZAPURINE RIBONUCLEOSIDES FOR THERAPEUTIC USES INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) 2016-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160159844-A1 NOVEL SUBSTITUTED 7-DEAZAPURINE RIBONUCLEOSIDES FOR THERAPEUTIC USES NSUN2, DUT, TYMP SLC29A1 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.